ClinicalTrials.gg
CompletedNCT02431442Updated May 1, 2015

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic Volunteers

A Phase 1 interventional study of RM-493 and Placebo in Overweight and Obese, sponsored by Rhythm Pharmaceuticals, Inc.. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-05-01.

Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the multiple dose safety and tolerability of RM-493 (setmelanotide) as well as pharmacokinetic (PK) and pharmacodynamic (PD; weight loss) profile, in healthy obese patients for 2 to 4 weeks. In addition, one panel of patients with a specific genetic deficiency in the hypothalamic leptin- proopiomelanocortin (POMC) - melanocortin-4 receptor (MC4R) pathway, those with heterozygous partial or full loss of function (LOF) of the MC4R gene, will also be studied. The study drug (RM-493 and placebo) will be administered subcutaneously in a blinded fashion by subcutaneous (SC) infusion or injection.

02

Conditions studied

  • Overweight
  • Obese

Keywords

  • Heterozygous
  • MC4R deficiency
  • associated
03

In context

Overweight

3,613 studies on the registry are indexed under Overweight; 861 are open to participants now.

This study's enrollment of 57 is below the median of 78 across 3,132 interventional studies indexed under Overweight.

Browse Overweight studies →

Lead sponsor

Rhythm Pharmaceuticals, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide voluntary, written with comprehension of all aspects of the protocol, prior to any study procedures.
  • Healthy obese male and female volunteers aged 18 to 55 years, inclusive. Heterozygous subjects may be 18 to 65 years inclusive.
  • In good general health, without significant medical history, physical examination findings, or clinical laboratory abnormalities.
  • of 30-40 kg/m2, inclusive. Heterozygous subjects may have a broader BMI range; to be eligible heterozygous subjects may have a BMI 27 -55 kg/ m2, inclusive.
  • Stable body weight during the previous 6 months, based on Investigator judgment.
  • Blood pressure \<140/90 mmHg at Screening and D-1. Measurement may be repeated within 24 hours, based on Investigator judgment.
  • Females must not be pregnant and must have a negative serum pregnancy test result at the Screening Visit and Day -1.
  • Females of must agree to be abstinent or else use any two of the following medically acceptable forms of from the Screening Period through the Final Study Visit: hormonal, condom with spermicidal jelly, diaphragm or cervical cap with spermicidal jelly, or IUD. Hormonal contraception must have started at least 3 months prior to screening. A female whose male partner has had a vasectomy must agree to use one additional form of medically acceptable contraception. Subjects must agree to practice the above birth control methods for 30 days from the final visit as a safety precaution.
  • Females of non-childbearing potential, defined as surgically sterile (status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or for at least 12 months (and confirmed with a screening FSH level in the post-menopausal range), do not require contraception during the study.
  • Males with female partners of childbearing potential must agree to use two medically acceptable forms of contraception as described above, with one of the two forms being condom with spermicide, from the Screening Period through the Final Study Visit. Males with female partners of childbearing potential who themselves are surgically sterile (status post vasectomy) must agree to use condoms with spermicide over the same period of time. Male subjects must agree to practice the above birth control methods for 30 days from the final visit as a safety precaution.

Exclusion criteria

Exclusion Criteria:

  • Fasting blood glucose >126 mg/dL at screening. Heterozygous subjects will be excluded for a fasting blood glucose >140 mg/dL.
  • Resting heart rate \<45 bpm or >90 bpm at screening.
  • Abnormal thyroid stimulating hormone (TSH) or thyroxine (T4) levels on screening.
  • Elevated or serum creatinine on screening or any abnormalities on screening laboratory tests as determined by the Investigator.
  • History of medically treated diabetes or of treated or medically diagnosed hypertension. Heterozygous subjects who have diagnosed hypertension and are well controlled on treatment (Refer to Exclusion Criteria 20 below), are eligible. .
  • Presence of a skin lesion suspicious for , unless excised prior to Day 1.
  • History of malignancy except for treated cervical carcinoma in situ in the past 5 years.
  • Active or history of any clinically significant medical condition including renal, hepatic, pulmonary, gastrointestinal, cardiovascular, genitourinary, endocrine, immunologic, metabolic, neurologic, psychiatric or hematological disease, based on Investigator judgment.
  • Acute illness or history of illness, which in the opinion of the Investigator, could pose a threat or harm to the subject or obscure interpretation of laboratory test results or interpretation of study data.
  • Positive surface antigen, positive antibody or positive test at screening or a history of positive testing (e.g. liver , serology) suggesting acute or chronic hepatitis.
  • Abnormal 12-lead (ECG) at screening or pre-dose (Day -1 or Day 1), except minor deviations deemed to be of no clinical significance by the Investigator.
  • Received any experimental drugs or devices within 30 days or 5 half lives, whichever is longer, prior to dosing.
  • Ongoing participation in a prior clinical study at the time of screening.
  • Blood donation within 60 days prior to screening or intent to donate within 60 days after Final Study Visit.
  • Hospitalization for major surgery including but not limited to abdominal, thoracic, or cardiovascular surgery within the past 3 months prior to screening, or for a clinically significant non-surgical illness, based on Investigator judgment, within the past 3 months.
  • Planned elective surgery within 30 days of the Final Study Visit.
  • Poor venous access or inability to tolerate venipuncture.
  • History of significant drug or anaphylaxis.
  • History of hypersensitivity to proteins (e.g., allergy shots).
  • Use of prescription medications on a regular basis. The last use of any prescription medication must have been greater than 5 half-lives for the specific medication or at least 14 days prior to admission (Day -1), whichever is longer. Hormonal is allowed for female subjects.

Heterozygous cohorts: Use of prescription medications on a regular basis is not allowed with the following exceptions:

  • Antihypertensives (\<3 medications on a stable dose for ≥ 30 days);
  • Statins (dose must be ≤ half the maximum dose; must be on a stable dose ≥3 months);
  • Fibrates (must be on stable dose for ≥3 months);
  • Niacin (must be on stable dose for ≥3 months);
  • Thyroxin (stable dose for ≥ 30 days); The last use of any other prescription medication will need follow the criteria for all other cohorts, as outlined above.

Use of prescription medications not listed above may be allowed at the discretion of the Investigator upon consultation with Rhythm.

  • Use of a non-prescription drug and herbal substances during the study (through the Final Study Visit). The last dose of any non-prescription drug must have been taken greater than 5 half-lives for that drug before receiving study drug.
  • Inability to attend all study visits or to comply with protocol requirements including fasting and restrictions on alcohol, caffeine, nicotine and concomitant medication intake.
  • A significant history of drug/solvent abuse within 5 years of screening or a positive test for drugs of abuse test at screening or on Day -1.
  • Positive alcohol (breath test) or nicotine screen at Screening Visit or Day 1 (positive nicotine screen does not apply to heterozygous cohort).
  • History of alcohol abuse (defined as average intake of three or more units of alcohol per day) within 5 years of the Screening Visit.
  • History of tobacco or tobacco product use unless abstinent for at least one year prior to the Screening Visit. This criterion does not apply to heterozygous subjects.
  • Previously randomized and dosed in this study. This criterion does not apply to heterozygous subjects.
  • Any other reason, which in the opinion of the Investigator would confound proper evaluation of the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
57 participants (actual)

Study arms

  • Active comparator
    Cohort 1: RM-493 SC Infusion 14 Days

    Double-blind RM-493 will be administered at a dose of 0.01 mg/kg/24 hours via subcutaneous continuous infusion for 14 days (1 panel, all male subjects)

    Drug: RM-493

  • Active comparator
    Cohort 2: RM-493 SC Infusion 28 Days

    Double-blind RM-493 will be administered at a dose of 0.01 mg/kg/24 hours via subcutaneous continuous infusion for 28 days (1 panel)

    Drug: RM-493

  • Active comparator
    Cohort 3: RM-493 SC Infusion 28 Days

    Double-blind RM-493 will be administered at a dose of 0.01 mg/kg/24 hours via subcutaneous continuous infusion for 28 days (1 panel)

    Drug: RM-493

  • Active comparator
    Cohort 4: RM-493 SC Infusion 28 Days

    Double-blind RM-493 will be administered at a dose of 0.015 mg/kg/24 hours via subcutaneous continuous infusion for 28 days (1 panel)

    Drug: RM-493

  • Active comparator
    Cohort 5: RM-493 SC Injection 14 days

    Double-blind RM-493 will be administered at a dose of 0.0075 mg/kg every 12 hours via a subcutaneous injection for 14 days (1 panel)

    Drug: RM-493

  • Active comparator
    Cohort 6: RM-493 SC Infusion 28 Days

    Double-blind RM-493 will be administered at a dose of 0.01 mg/kg/24 hours via subcutaneous continuous infusion for 28 days (1 panel, heterozygous MC4R subjects)

    Drug: RM-493

  • Placebo comparator
    Cohort 1: Placebo SC Infusion 14 Days

    Double-blind Placebo will be administered via subcutaneous continuous infusion for 14 days (1 panel, all male subject)

    Drug: Placebo

  • Placebo comparator
    Cohort 2: Placebo SC Infusion 28 Days

    Double-blind Placebo will be via subcutaneous continuous infusion for 14 days (1 panel)

    Drug: Placebo

  • Placebo comparator
    Cohort 3: Placebo SC Infusion 28 Days

    Double-blind Placebo will be administered via subcutaneous continuous infusion for 28 days (1 panel)

    Drug: Placebo

  • Placebo comparator
    Cohort 4: Placebo SC Infusion 28 Days

    Double-blind Placebo will be administered via subcutaneous continuous infusion for 28 days (1 panel)

    Drug: Placebo

  • Placebo comparator
    Cohort 5: Placebo SC Injection 14 days

    Double-blind Placebo will be administered via a subcutaneous injection every 12 hours for 14 days (1 panel)

    Drug: Placebo

  • Placebo comparator
    Cohort 6: Placebo SC Infusion 28 Days

    Double-blind Placebo will be administered via subcutaneous continuous infusion for 28 days (1 panel, heterozygous MC4R subjects)

    Drug: Placebo

Interventions

  • DrugRM-493

    Also known as: setmelanotide

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Number of adverse events.

    Time frame: Day 1 through Day 14 or Day 28 (depending on Cohort)

Secondary outcomes

  1. Pharmacokinetics (PK) Profile

    Frequent PK (trough) sampling throughout the study, including 24-hour inpatient PK profiles at the beginning and end of the study.

    Time frame: Day 1 through Day 14 or Day 28 (depending on Cohort)

  2. Assessment of weight loss based on weight measurements

    Time frame: Day 1 through Day 14 or Day 28 (depending on Cohort)

  3. Assessment of blood pressure using Ambulatory blood pressure monitors.

    Time frame: Day 1 through Day 14 or Day 28 (depending on Cohort)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2015
First posted
May 1, 2015
Start
Jan 2012
Primary completionActual
Jan 2014
CompletionActual
Jan 2014
Last update
May 1, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02431442
Responsible party
Sponsor
First posted
May 1, 2015
Start date
Jan 2012
Primary completion
Jan 2014
Completion
Jan 2014
Last update
May 1, 2015

Study contacts

Elizabeth Stoner, MD
study director · Rhythm Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Setmelanotide

Start the discussion